A Study to Evaluate the Safety, Tolerability, and Effects of Anatabloc® Crème in Rosacea

An Eight-Week, Multi-Site, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Trial to Evaluate the Safety, Tolerability, and Effects of Anatabloc® Crème in Subjects With Rosacea Followed by an Open-Label Extension

This is a multi-site, four-visit, eight-week, double-blind, randomized, vehicle-controlled, parallel-group study followed by an eight-week open-label extension to evaluate the safety, tolerability, and potential effects of Anatabloc Facial Cream. The secondary aim is to evaluate if Anatabloc Facial Cream improves the appearance of the skin in subjects with mild to moderate rosacea.

Inclusion Criteria:

• age between 25-70 years
• diagnosed with mild to moderate rosacea

Exclusion Criteria:

• allergy or sensitivity to the study products or their components
• severe rosacea
• current use of glucocorticoids, anti-acne products, antibiotics, topical retinoids, or vasoactive drugs
• recent oral isotretinoin use
• current use of anatabine-containing supplements (ie. Anatabloc, Anatabloc Unflavored, CigRx)